Table 4.

Recommendations of intravesical therapy for low and intermediate risk patients^a

Guideline ID	Low risk	Intermediate risk
	Induction	Induction				Maintenance
	Not be recommended	Be recommended		Course of treatment		Be recommended		Course of treatment
	SOR/LOE	Chemotherapy	BCG			Chemotherapy	BCG	Chemotherapy		BCG
		SOR/LOE	SOR/LOE	Course	SOR/LOE	SOR/LOE	SOR/LOE	Course	SOR/LOE	Course	SOR/LOE
ESMO, 2014 [8]	−/−	−/−	−/−	–	−/−	−/−	−/−	–	−/−	–	−/−
NICE, 2015 [9]b	−/−	A/high-low	−/−	At least 6 doses	A/high-low	−/−	−/−	–	−/−	–	−/−
CUA, 2015 [10]	−/−	B/−	B/−	–	−/−	B/−	B/−	1 years	B/−	–	−/−
AUA/SUO, 2016 [3]	Moderate/C	Moderate/B	Moderate/B	6 weeks	Moderate/B	Conditional/C	Moderate/C	–	−/−	1 year	Moderate/C
JUA, 2016 [11]	−/−	−/−	−/−	–	−/−	−/−	−/−	–	−/−	–	−/−
EAU, 2018 [12]	−/−	−/−	Strong/1a-3	–	−/−	Strong/1a-3	Strong/1a-3	≤ 1 years	Weak/3	Full dose, 1 year Three-weekly instillations at 3, 6 and 12 months	Strong/1a-1b
ICUD/SIU, 2018 [13]	A/1a	B/2a	A/1a	–	−/−	B/2a	A/1a	6-12 months	B/2a	Full dose, 1 year	A/1a
CRHA/CPAM, 2018 [14]	B/1a	A/1a	B/1a-1b	Weekly for 4–8 weeks	A/1a	A/1a	A/1a	Monthly for 6–10 months	A/1a	Low dose	B/1a-1b
										1–3 years	B/1b
NCCN, 2019 [15]c	−/−	B/2A	A/2A	Initiated 3–4 weeks after TURBT	B/2A	B/2A	A/2A	–	−/−	1 year	B/2A
				Weekly for 6 weeks	B/2A

^a The SOR and LOE are presented as “SOR/LOE”. “-” indicates that the recommendation or evidence was not presented

^b To simplify the table, we used “A” and “B” instead of “should/should not/offer/do not offer/refer/advise” or “consider” for presenting SOR

^c To simplify the table, we used “A” and “B”, “C” instead of “preferred intervention”, “other recommended intervention”, or “useful in certain circumstances” for presenting SOR